Jinwu Financial News | According to Debon Securities Research, Collumbotai Biotech (06990) earned 1.383 billion yuan in the first half of 2024, an increase of 32.2%. This increase was mainly due to the increase in milestone payments and cooperative payments due to the cooperation agreement signed with MSD. Gross profit for the first half of the year reached 1.077 billion yuan, up 59.4% year on year, net profit was 0.31 billion yuan, and loss was 31.13 million yuan in the same period last year. R&D expenditure in the first half of the year was RMB 0.652 billion, up 33% year on year.
The bank expects to launch core products SAC-TMT (Cathay), A166 (Sutelai), and main products A167 (Cotailai) and A140 (Datailai) in the Chinese market in the second half of 2024 or the first half of 2025. The company has formed a mature commercialization team dedicated to preparing and implementing the marketing and commercialization of strategic products.
The bank said that at present, the company has established a strong pipeline with more than ten clinical-stage drug candidates. Four of them are in the NDA application stage. The pipeline is rich, and the overseas value of ADC is gradually highlighted. It is estimated that its 24-26 revenue will be 1.744, 1.62, and 2.688 billion yuan. Maintain a “buy” rating.
